The Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for treatment of patients with metastatic non-small cell lung cancer (NSCLC). Blueprint Medicines Corporation is a precision therapy company focused on genomically…
Everything about lung cancer is here.
The Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for treatment of patients with metastatic non-small cell lung cancer (NSCLC). Blueprint Medicines Corporation is a precision therapy company focused on genomically…